Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867012566648094720 |
|---|---|
| author | Andrée‐Ann Baril Cynthia Picard Anne Labonté Erlan Sanchez Catherine Duclos Béry Mohammediyan Nicholas J. Ashton Henrik Zetterberg Kaj Blennow John C. S. Breitner Sylvia Villeneuve Judes Poirier |
| author_facet | Andrée‐Ann Baril Cynthia Picard Anne Labonté Erlan Sanchez Catherine Duclos Béry Mohammediyan Nicholas J. Ashton Henrik Zetterberg Kaj Blennow John C. S. Breitner Sylvia Villeneuve Judes Poirier Andrée‐Ann Baril Cynthia Picard Anne Labonté Erlan Sanchez Catherine Duclos Béry Mohammediyan Nicholas J. Ashton Henrik Zetterberg Kaj Blennow John C. S. Breitner Sylvia Villeneuve Judes Poirier |
| collection | Wiley Open Access |
| contents | Day‐to‐day sleep variability with Alzheimer's biomarkers in at‐risk elderly Andrée‐Ann Baril Cynthia Picard Anne Labonté Erlan Sanchez Catherine Duclos Béry Mohammediyan Nicholas J. Ashton Henrik Zetterberg Kaj Blennow John C. S. Breitner Sylvia Villeneuve Judes Poirier Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring AbstractINTRODUCTIONMeasuring day‐to‐day sleep variability might reveal unstable sleep‐wake cycles reflecting neurodegenerative processes. We evaluated the association between Alzheimer's disease (AD) fluid biomarkers with day‐to‐day sleep variability.METHODSIn the PREVENT‐AD cohort, 203 dementia‐free participants (age: 68.3 ± 5.4; 78 males) with a parental history of sporadic AD were tested with actigraphy and fluid biomarkers. Day‐to‐day variability (standard deviations over a week) was assessed for sleep midpoint, duration, efficiency, and nighttime activity count.RESULTSLower cerebrospinal fluid (CSF) ApoE, higher CSF p‐tau181/amyloid‐β (Aβ)42, and higher plasma p‐tau231/Aβ42 were associated with higher variability of sleep midpoint, sleep duration, and/or activity count. The associations between fluid biomarkers with greater sleep duration variability were especially observed in those that carried the APOE4 allele, mild cognitive impairment converters, or those with gray matter atrophy.DISCUSSIONDay‐to‐day sleep variability were associated with biomarkers of AD in at‐risk individuals, suggesting that unstable sleep promotes neurodegeneration or, conversely, that AD neuropathology disrupts sleep‐wake cycles. 10.1002/dad2.12521 http://creativecommons.org/licenses/by-nc/4.0/ |
| doi_str_mv | 10.1002/dad2.12521 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_dad2_12521 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Day‐to‐day sleep variability with Alzheimer's biomarkers in at‐risk elderly Andrée‐Ann Baril Cynthia Picard Anne Labonté Erlan Sanchez Catherine Duclos Béry Mohammediyan Nicholas J. Ashton Henrik Zetterberg Kaj Blennow John C. S. Breitner Sylvia Villeneuve Judes Poirier Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring Day‐to‐day sleep variability with Alzheimer's biomarkers in at‐risk elderly Andrée‐Ann Baril Cynthia Picard Anne Labonté Erlan Sanchez Catherine Duclos Béry Mohammediyan Nicholas J. Ashton Henrik Zetterberg Kaj Blennow John C. S. Breitner Sylvia Villeneuve Judes Poirier Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring AbstractINTRODUCTIONMeasuring day‐to‐day sleep variability might reveal unstable sleep‐wake cycles reflecting neurodegenerative processes. We evaluated the association between Alzheimer's disease (AD) fluid biomarkers with day‐to‐day sleep variability.METHODSIn the PREVENT‐AD cohort, 203 dementia‐free participants (age: 68.3 ± 5.4; 78 males) with a parental history of sporadic AD were tested with actigraphy and fluid biomarkers. Day‐to‐day variability (standard deviations over a week) was assessed for sleep midpoint, duration, efficiency, and nighttime activity count.RESULTSLower cerebrospinal fluid (CSF) ApoE, higher CSF p‐tau181/amyloid‐β (Aβ)42, and higher plasma p‐tau231/Aβ42 were associated with higher variability of sleep midpoint, sleep duration, and/or activity count. The associations between fluid biomarkers with greater sleep duration variability were especially observed in those that carried the APOE4 allele, mild cognitive impairment converters, or those with gray matter atrophy.DISCUSSIONDay‐to‐day sleep variability were associated with biomarkers of AD in at‐risk individuals, suggesting that unstable sleep promotes neurodegeneration or, conversely, that AD neuropathology disrupts sleep‐wake cycles. 10.1002/dad2.12521 http://creativecommons.org/licenses/by-nc/4.0/ |
| title | Day‐to‐day sleep variability with Alzheimer's biomarkers in at‐risk elderly |
| topic | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring |
| url | https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12521 |